Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Dr Judith Balmaña
Dr Rebecca Dent
Prof. Simon Boulton
Prof. Sibylle Loibl
Prof. Eric Pujade-Lauraine
Prof. Charlie Gourley
Dr Violeta Serra
Prof. Jonathan A. Ledermann
Publication Date
Sep 2021
Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca.
Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Artios Pharma Ltd.
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca and Tesaro.
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
DOWNLOAD THE SLIDES 
Programme summary
Duration 10 MIN- Downloadable resources Yes
-
DOWNLOAD THE SLIDES
-
Language(s)
Duration 
Language(s)
Share this programme
Other programmes of interest
Other
Oncology
The evolving role of liquid biopsy in biomarker testing
Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer
Experts
Assoc. Prof. Umberto Malapelle-
Downloadable
Resources -
5 MIN
-
Jul 2024
Downloadable 
5 MIN
Jul 2024 
Interactive patient case
Oncology
Advanced renal cell carcinoma: Managing a long-term durable response
Maximising outcomes for patients with advanced RCC
Experts
Prof. Michael StaehlerEndorsed by
-
15 MIN
-
Jun 2024
Other
Episode
1
of 1
Oncology
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer
Medical experts make recommendations for best practice
Experts
Dr Alexander Wyatt, Prof. Frédéric BibeauEndorsed by
-
Downloadable
Resources -
5 MIN
-
Jun 2024
Conference update
Oncology
Oncogene-addicted NSCLC: Highlights from ASCO 2024
The latest non-small cell lung cancer data presented at ASCO
Experts
Prof. Nicolas Girard-
Downloadable
Resources -
3 MIN
-
Jun 2024
Conference update
Oncology
Upper and lower GI cancer update from ASCO 2024
GI oncologists review the latest data presented at ASCO 2024
Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest-
8 MIN
-
Jun 2024
Oncology Hemato-oncology
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)
Medical experts discuss the latest learnings from clinical practice
Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter-
Downloadable
Resources -
76 MIN
-
Jun 2024
